Skip to content

Erasca, Inc. ERAS Research and development expense

Research and development expense at other companies

Eli Lilly logo
Eli LillyLLY
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s research and development expense?
Erasca, Inc. (ERAS) reported research and development expense of $27.27M in Q1 2026.
How has Erasca, Inc.'s research and development expense changed year-over-year?
Erasca, Inc.'s research and development expense increased by 5.0% year-over-year, from $25.97M to $27.27M.
What is the long-term trend for Erasca, Inc.'s research and development expense?
Over 4 years (2021 to 2025), Erasca, Inc.'s research and development expense has grown at a 5.9% compound annual growth rate (CAGR), from $73.92M to $92.85M.